【Objective】 To assess the efficacy and toxicity of adding bevacizumab to XELOX induction chemotherapy followed by preoperative bevacizumab-based chemoradiotherapy in patients with locally advanced rectal cancer. 【Methods】Eligible patients had high-risk rectal adenocarcinoma defined by magnetic resonance imaging criteria. Treatment consisted of four 21-day cycles of bevacizumab(7.5 mg/kg) and XELOX(capecitabine plus oxaliplatin), followed by concomitant radiotherapy(50.4 Gy) plus bevacizumab(5 mg/kg, every 2...